Syndax Pharmaceuticals, Inc.
SNDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$318,758 | -$209,360 | -$149,338 | $24,926 |
| Dep. & Amort. | $8 | $12 | $33 | $43 |
| Deferred Tax | $0 | $0 | $0 | $255 |
| Stock-Based Comp. | $43,026 | $30,951 | $16,019 | $13,317 |
| Change in WC | $13,270 | $31,860 | $1,656 | -$9,597 |
| Other Non-Cash | -$12,449 | -$14,064 | -$2,045 | $187 |
| Operating Cash Flow | -$274,903 | -$160,601 | -$133,675 | $29,131 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | $0 | $0 | -$225 | -$129 |
| Net Acquisitions | $0 | $0 | $225 | $41 |
| Inv. Purchases | -$557,052 | -$354,606 | -$495,346 | -$294,719 |
| Inv. Sales/Matur. | $337,277 | $472,215 | $308,933 | $253,975 |
| Other Inv. Act. | $0 | $0 | $225 | -$41 |
| Investing Cash Flow | -$219,775 | $117,609 | -$186,188 | -$40,873 |
| Financing Activities | – | – | – | – |
| Debt Repay. | $0 | $0 | -$20,996 | $0 |
| Stock Issued | $9,715 | $258,094 | $181,390 | $86,337 |
| Stock Repurch. | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | $343,652 | $6,038 | $11,860 | $32,127 |
| Financing Cash Flow | $353,367 | $264,132 | $172,254 | $118,464 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$141,311 | $221,140 | -$147,609 | $106,722 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $295,611 | $74,471 | $222,080 | $115,358 |
| End Cash | $154,300 | $295,611 | $74,471 | $222,080 |
| Free Cash Flow | -$274,903 | -$160,601 | -$133,900 | $29,002 |